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Purpose
Evaluate pre-treatment muscle biopsies of patient’s with
probable or definite Juvenile Dermatomyositis (JDM)
using the Wedderburn score to predict clinical
outcomes.
Background
JDM is the most common idiopathic inflammatory myo-
pathy in children. The Wedderburn scoring system is
used to assess JDM muscle biopsies and categorizes mus-
cle involvement into 4 domains: inflammatory, vascular,
muscle fiber and connective tissue fibrosis (maximum
scores: 12, 3, 10, and 2, respectively) and a 10-cm VAS
measuring overall abnormality. A 10 cm VAS for chroni-
city (endomysial fibrosis, capillary loss and central nuclei)
was also measured.
Methods
In this retrospective cohort study JDM patients diag-
nosed from 1995-2008 underwent pre-treatment muscle
biopsy guided by soft tissue MRI at CCHMC. Children
had probable or definite JDM (Bohan and Peter criteria)
and disease duration ≥ 2 years. Disease was classified as
“limited” or “chronic” based on treatment duration and
chronic disease was subdivided into “nonulcerative” or
“ulcerative” (cutaneous or gastrointestinal ulcers) (Crowe
et al, 1982). Demographics, disease manifestations, com-
plications and treatment duration were collected. Severity
of muscle weakness was assessed at presentation, 2 years,
and last visit. Muscle biopsies were evaluated jointly by 2
pathologists using the Wedderburn scoring system. Wil-
coxon Sign Rank Test and Spearman Correlation Coeffi-
cient (CC) were used.
Results
22 patients were studied with mean (median) age at
diagnosis 7.4 ys (6.5), follow up duration 49.5 months
(47.5) and treatment duration 44.1 months (35). 2
patients had limited disease and 20 chronic disease, all
were nonulcerative. Patients had mild or moderate
weakness at first visit and no or mild weakness at 2 ys
and final visit. Mean (median) Wedderburn scores were
as follows: inflammatory 6 (6.5), vascular 0.9 (1), muscle
fiber 5.8 (6), connective tissue fibrosis 1 (1), VAS overall
3.6 (3.2), and VAS chronicity 2.1 (1.1). The connective
tissue fibrosis domain and the VAS chronicity score had
the strongest correlations with muscle weakness at the
final visit and moderate correlations with muscle weak-
ness at all visits. (Table 1) Statistical significance was
limited by the small sample size. There were no patients
with very poor outcomes (e.g. death, ulcerative disease).
Conclusion
The Wedderburn connective tissue fibrosis domain
score associates with severity of muscle weakness. No
other significant correlations. The VAS chronicity score
is moderately associated with final muscle weakness,
suggesting endomysial fibrosis, capillary loss and central
nuclei in nonmyopathic fibers in pre-treatment muscle
biopsies as predictors of disease outcome. Table 1.
Results of the Wedderburn score and correlation with
weakness and clinical data.
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Table 1
Domain or VAS Weakness 1st visit Weakness 2 years Weakness final Disease type Treatment duration
Connective tissue fibrosis CC=0.4 CC=0.4 CC=0.4 CC=0.01 CC=0.1
p=0.04 p=0.06 p=0.06 p=1 p=0.5
Muscle CC=0.2 CC=0.03 CC=0.06 CC=0.3 CC=0.3
p=0.4 p=0.9 p=0.8 p=0.2 p=0.2
Inflammatory CC=03 CC=-0.1 CC=0.1 CC=0.2 CC=0.3
p=0.2 p=0.7 p=0.6 p=0.4 p=0.2
Vascular CC=0.3 CC=0.1 CC=0.3 CC=0.2 CC=0.4
p=0.1 p=0.5 p=0.2 p=0.4 p=0.1
Overall biopsy score (VAS) CC=0.2 CC=0,1 CC=0.2 CC=0.2 CC=0.02
p=0.3 p=0.6 p=0.5 p=0.3 p=0.9
CC=0.3 CC=0.3 CC=0.4 CC=0.1 CC=0.2
p=0.1 p=0.1 p=0.07 p=0.7 p=0.3
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